Epidemiology of hepatitis B virus infection in a US cohort of HIV-infected individuais during the past 20 years

Clinical Infectious Diseases

Volumn 50, Issue 3, 2010, Pages 426-436

  Chun, Helen M ^a   Fieberg, Ann M ^b,c   Hullsiek, Katherine Huppler ^b,c   Lifson, Alan R ^b,c   Crum Cianflone, Nancy F ^a,c   Weintrob, Amy C ^c,e   Ganesan, Anuradha ^c,d   Barthel, Robert V ^f   Bradley, William P ^c,g   Agan, Brian K ^c   Landrum, Michael L ^c,g  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^f NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^g SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HEPATITIS B VACCINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MORBIDITY; PREVALENCE; PRIORITY JOURNAL; UNITED STATES;

ADULT; COHORT STUDIES; FEMALE; HEPATITIS B; HIV INFECTIONS; HUMANS; MALE; PREVALENCE; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 75749135627     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/649885     Document Type: Article

References (37)

1. Chun H, Landrum ML. Liver-related complications in HIV-infected individuals. Infect Dis Clin Practice 2007; 15:38-48.
2. Sulkowski MS. Management of hepatic complications in HIV-infected persons. J Infect Dis 2008; 197:S279-S293.
3. Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641. (Pubitemid 44232373)
4. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006; 44:S65-S70. (Pubitemid 43053877)
5. Thio C, Seaberg E, Skolasky R. HIV-1, hepatitis B virus, and risk of liver-related mortality in the MACS. Lancet 2002; 360:1921-1926.
6. Soriano V, Puoti M, Bonacini M, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B virus international panel. AIDS 2008; 22:1399-1410.
7. Konopnicki D, Mocroft A, de Wit S, et al.; EuroSIDA Group. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:393-601.
8. Tedaldi E, Peters L, Neuhaus J, et al. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the Strategic Management of Antiretroviral Therapy (SMART) Study. Clin Infect Dis 2008; 47:1468-1475.
9. Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral treatment of HIV infection. 2008 recommendations of the International AIDS SocietyUSA Panel. JAMA. 2008; 300:555-570.
10. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008; 1-128. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed June 2008.
11. Sulkowski M, Thomas DL, Chaisson R, Moore R. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B infection. JAMA. 2000; 283:74-80. (Pubitemid 30038386)
12. Sulkowski M, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182-189. (Pubitemid 34032559)
13. den Brinker M, Wit FWNM, Dillen PMEW, et al. Hepatitis B and C virus co-infection and the risk for hepatoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14:2895-2902. (Pubitemid 32042753)
14. Sungkanuparph S, Vibhagool A, Manosuthi W, et al. Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study. J Med Assoc Thai 2004; 87:1349-1354. (Pubitemid 40238559)
15. Tien PC, Kovacs A, Bacchetti P, et al. Association between syphilis, antibodies to herpes simplex virus type 2, and recreational drug use and hepatitis B virus infection in the Women's Interagency HIV Study. Clin Infect Dis 2004; 39:1363-1370. (Pubitemid 39458524)
16. Ockenga J, Tillman HL, Trautwein C, Stall M, Manns MP, Schmidt RE. Hepatitis B and C in HIV-infected patients. J Hepatol 1997; 27: 18-24.
17. Holland CA, Yong MA, Moscicki AB, Durako SJ, Levin L, Wilson CM. Seroprevalence and risk factors of hepatitis B, hepatitis C, and human cytomegalovirus among HIV-infected and high-risk uninfected adolescents: findings of the REACH study. Adolescent. Medicine HIV/AIDS Research Network. Sex Transm Dis 2000; 27:296-303.
18. Saillour F, Dabis F, Dupon M, et al. Prevalence and determinants of antibodies to HCV and markers of HBV infection in patients with HIV infection in Aquitaine. BMJ 1996; 313:461-464. (Pubitemid 26280351)
19. Tovo CV, Dos Santos DE, de Mattos AZ, Almeida PRL, Mattos AA, Santos BR. Ambulatorial prevalence of hepatitis B and C markers in patients with human immunodeficiency virus infection in a general hospital [in Potuguese]. Arq Gastroenterol 2006; 43:73-76. (Pubitemid 44401014)
20. Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected participants. J Infect Dis 2003; 188:571-577.
21. Kim WR. Epidemiology of hepatitis B in the United States. Hepatology 2009; 49:s28-s34.
22. Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis-United States, 2006. MMWR Surveill Summ 2008; 57:1-24.
23. Goldstein ST, Alter MJ, Williams IT, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. J Infect Dis 2002; 185:713-719.
24. Centers for Disease Control and Prevention. Incidence of acute hepatitis B-United States, 1990-2002. MMWR Morb Mortal Wkly Rep 2004; 52:1252-1254.
25. Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005; 104:1505-1511. (Pubitemid 41356166)
26. Weintrob AC, Fieberg AM, Agan BK, et al. Increasing age at HIV seroconversion from 18 to 40 years is associated with favorable virologic and immunologic responses to HAART. J Acquir Immune Defic Syndr 2008; 49:40-47.
27. Brodine SK, Starkey MJ, Shaffer RA, et al. Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS 2003; 17:2521-2527.
28. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41(RR-17):1-19.
29. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Amer Stat. Assoc 1979; 74:829-836.
30. Landrum ML, Hullsiek KH, Ganesan A, et al.; for the Infectious Disease Clinical Research Program HIV Working Group. Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS 2009 (Epub ahead of print).
31. Army Medical Surveillance Activity. Vaccine-preventable diseases, military members and other beneficiaries of the U.S. military health system, 2005-2006. Med Surveill Monthly Rep 2007; 13:13-17.
32. Heffelfinger JD, Swint EB, Berman SM, Weinstock HS. Trends in primary and secondary syphilis among men who have sex with men in the United States. Am J Public Health 2007; 97:1076-1083. (Pubitemid 351181931)
33. Centers for Diseases Control and Prevention. Trends in reportable sexually transmitted diseases in the United States, 2007: national surveillance data for chlamydia, gonorrhea, and syphilis. 2009. Available at: http://www.cdc.gov/std/stats07/trends.pdf Accessed 15 April 2009.
34. Wolitski RJ, Parsons JT, Gomez CA. Prevention with HIV-seropositive men who have sex with men: lessons learned from the seropositive urban men's study (SUMS) and the seropositive urban men's intervention trial (SUMIT). J Acquir Immune Defic Syndr 2004;37:s101s109.
35. Lin JS, Whitlock E, O'Connor E, Bauer V. Behavioral counseling to prevent sexually transmitted infections: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149:497-508.
36. Centers for Disease Control and Prevention. Incorporating HIV prevention into the medical care of persons living with HIV: recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR. Recomm Rep 2003; 52:1-24; erratum: MMWR Recomm Rep 2004; 53:744.
37. Sheng W, Kao J, Chen P, et al. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 2007; 45:1221-1229. (Pubitemid 47580325)